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Abstract: Performance of the QuantiFERON-TB Gold Plus (QFT-Plus) assay could be affected by
conditions of immune dysregulation. Little is known about the reliability of QTF-Plus in COVID-19
patients. Our aim was to determine the prevalence and the factors related to an indeterminate
QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with in-hospital
mortality. A retrospective analysis of all hospitalized COVID-19 patients on whom a QTF-Plus assay
was performed in a tertiary care public hospital during the first epidemic wave in Spain (March–April
2020). Out of a total of 96 patients included, 34 (35.4%) had an indeterminate result, in all cases due to
a lack of response in the mitogen control. Factors related to COVID-19 severity, such as higher lactate
dehydrogenase (LDH) (odds ratio [OR] 1.005 [95% confidence interval [CI] 1.002–1.008]) and previous
administration of corticosteroids (OR 4.477 [95% CI 1.397–14.345]), were independent predictors
for indeterminate QFT-Plus assay. Furthermore, indeterminate results were more frequent among
COVID-19 patients who died during hospitalization (29.1% vs. 64.7%; p = 0.005). We conclude that
QFT-Plus assay yielded an unexpected, high prevalence of indeterminate results in severe COVID-
19 patients. Factors related to worse COVID-19 outcome, such as LDH, as well as corticosteroid
use before the QFT-Plus assay, seem to be predictors for an indeterminate result. The role of an
indeterminate QFT-Plus result in predicting COVID-19 severity and mortality should be evaluated.
Keywords: QuantiFERON-TB Gold Plus; indeterminate; COVID-19; SARS-CoV-2; corticosteroids
1. Introduction
In December 2019, an emerging disease (COVID-19), caused by a newly identified
human coronavirus, was first recognized in Wuhan, China, and spread worldwide [1,2].
The WHO declared the COVID-19 epidemic to be a pandemic on 12 March 2020 [3],
and it continues to spread globally today, causing considerable morbimortality and eco-
nomic damage.
Multiple drugs have been repurposed to treat severe SARS-CoV-2 infections presenting
with systemic hyperinflammatory syndrome, some of them having an immunosuppressive
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effect such as corticosteroids, tocilizumab, anakinra, etc. [4–7]. Therefore, reactivation of
several dormant infections, including latent tuberculosis infection (LTBI), is of concern
among COVID-19-treating physicians. In this regard, interferon-gamma release assays
(IGRAs), such as the QuantiFERON-TB Gold Plus (QFT-Plus; Qiagen, Germany) [8] assay,
have been unsystematically performed for LTBI screening in some severe COVID-19
patients, before or during immunosuppressive therapy.
QFT-Plus is based on the detection of interferon-gamma (IFN-γ) released by a T-
cell-mediated immune response following in vitro stimulation of human whole-blood
by antigens specific to the Mycobacterium tuberculosis complex [8]. Additionally, the
QFT-Plus assay includes a mitogen-based control designed to nonspecifically elicit a T-
cell response and thus infer the immunological fitness of the studied individuals. It is
well known that active inflammation or immunosuppressive drug use is associated with
QFT-Plus indeterminate results [8,9].
During the first months of the COVID-19 pandemic, microbiologists observed a
surprisingly high rate of QFT-Plus indeterminate results in patients hospitalized with
COVID-19 at our hospital. At that time, there was no information about this finding and,
nowadays, there is still little information about how COVID-19 itself and the immunosup-
pressive drugs can impact QFT-Plus performance [10]. In addition, it is not known if an
indeterminate QFT-Plus result might have a relation to COVID-19 severity and mortality.
Our aim was to determine the prevalence and the factors related to an indeterminate
QFT-Plus test in COVID-19 hospitalized patients, and to analyze its relationship with
in-hospital mortality.
2. Materials and Methods
2.1. Study Design and Participants
The study was conducted at the Bellvitge University Hospital (BUH), a 750-bed
tertiary-care public hospital for adults in Barcelona, Spain. BUH is the reference hospital for
2 million inhabitants with high-complexity diseases from the Southern area of Catalonia.
We performed a retrospective study of all hospitalized patients with COVID-19 from
March to April 2020. SARS-CoV-2 infection was confirmed by RT-PCR in all patients on
whom the QFT-Plus test was performed. Demographic, epidemiological, laboratory and
clinical data were also collected. Laboratory tests were determined within 24 hours before
or after the QFT-Plus test. The QFT-Plus indeterminate results were defined according
to the manufacturer´s criteria. Nil value comes from the negative control tube that con-
tains no additives, and it is used to determine if the patient has a pre-existing immune
disturbance which could cause a false-positive or false-negative reading on the test (that
is, nil > 8 UI/mL or nil-corrected mitogen value < 0.5 IU/mL) [8]. Mild hypoxemia was
defined as PF (PaO2/FiO2) ratio < 300 and/or SF (SpO2/FiO2) ratio < 357; moderate hy-
poxemia was defined as PF ratio < 200 and/or SF ratio < 214; and severe hypoxemia was
defined as PF ratio < 100 and/or SF ratio < 89) [11]. In accordance with the WHO 8-point
ordinal scale [12], a moderate disease was defined as hospitalized patients with or without
supplementary oxygen; and a severe disease was considered in patients with non-invasive
ventilation or high-flow oxygen, intubation and mechanical ventilation, additional organ
support, renal replacement treatment or extracorporeal membrane oxygenation (ECMO), or
death. We calculated the WHO 8-point ordinal scale corresponding to the same day that the
QFT-Plus assay was performed for each participant. Treatments specifically used to treat
COVID-19 at any time during admission, and immunosuppressive treatments administered
before the QFT-Plus test was performed were also analyzed. According to the March to
April 2020 BUH guidelines, corticosteroids were administered as methylprednisolone iv
125 mg daily on 3 consecutive days, and iv tocilizumab as a single dose (600 mg if ≥75 kg
or 400 mg if <75 kg). Length of stay from QFT-Plus assay until hospital discharge or death
was also recorded.
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2.2. Statistical Analysis
Results from continuous variables are presented as median and interquartile range
(IQR), and categorical data as absolute frequencies and percentages. Comparisons of the
cohorts were made using a chi-square test or Fisher’s exact test for categorical variables and
a Mann–Witney U test for continuous variables. Multivariable logistic regression analysis
using the stepwise method was performed to assess factors related to an indeterminate
QFT-Plus assay result for not inter-correlated and univariate p-value ≤ 0.1 co-variables,
since we do not know which ones may be the most relevant due to the lack of previous
studies in patients with COVID-19. Survival analysis was conducted using Cox univariate
regression and Kaplan–Meier curves to assess the impact of an indeterminate QFT-Plus
assay on the COVID-19 in-hospital mortality. Statistical significance was defined as p-value
< 0.05 and we also used odds ratios (OR) or hazard ratios (HR) and their 95% confidence
intervals (CI). Calculations were performed with the statistical package SPSS version 19
(IBM Corp., USA).
3. Results
The QFT-Plus test was performed on 96 (6.8%) of a total of 1403 patients admitted
due to COVID-19 during the study period. Main comorbidities, clinical status, laboratory
tests and treatment characteristics are summarized in Table 1. In all cases, the QFT-Plus
assay was indicated for the screening of LTBI in patients receiving or potentially going
to receive immunosuppressive therapy to treat severe COVID-19. Finally, of the overall
96 cases, 66 (68.8%) received corticosteroids and/or tocilizumab, and the rest did not. The
QFT-Plus test was performed with a median of 12 (IQR 10–16) days from the onset of
COVID-19 symptoms. Of the overall 96 patients tested, 54 (56.3%) were negative, 8 (8.3%)
were positive, and 34 (35.4%) were indeterminate. Any patient developed tuberculosis
after a median follow-up period of 74 days (IQR 61–78). All indeterminate results were
due to a lack of response to the mitogen control.
There was a significant association between an indeterminate QFT-Plus result and lym-
phopenia (0.64 [0.48–1.15] vs. 0.88 [0.64–1.27] × 109; p = 0.017), leukocytosis (8.6 [6.3–13.9]
vs. 6.8 [5.6–9.6] × 109; p = 0.016), and neutrophilia (7.3 [5.4–12.4] vs. 5.5 [3.5–8.3] × 109;
p = 0.002). Indeterminate QFT-Plus assay results were associated with higher levels of
lactate dehydrogenase (LDH) (412 [330–517] vs. 317 [265–424] U/L; p = 0.003) and D-
dimer (636 [353–2913] vs. 361 [250–946] µg/L; p = 0.025), as well as hypoxemia (p = 0.015).
Additionally, corticosteroid use prior to the QFT-Plus test was significantly higher in the
indeterminate subset (n = 10/34 [29.4%] vs. n = 6/62 [9.7%]; p = 0.013). Significantly,
five of the 34 (14.7%) patients who did not receive immunosuppressive treatment prior
to testing showed indeterminate results. However, no association between indeterminate
QFT-Plus and age, gender, comorbidities or previous days of COVID-19 was found. In the
adjusted analysis, higher LDH (OR 1.005 [95% CI 1.002–1.008]) and corticosteroid use before
performing the QFT-Plus test (OR 4.477 [95% CI 1.397–14.345]) remained independently
associated with an indeterminate test (Table 1).
Seventeen (17.7%) patients died during hospitalization. In this respect, a significant
association was found between mortality and an indeterminate QFT-Plus assay result
(n = 23/79 [29.1%] vs. n = 11/17 [64.7%]; p = 0.005). Patients with an indeterminate
QFT-Plus test showed four times more risk for in-hospital mortality (HR 4.025 [95% CI
1.486–10.903]) than those patients with interpretable results (Figure 1).
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Table 1. Main characteristics of 96 COVID-19 hospitalized patients according the QuantiFERON-TB Gold Plus (QFT-Plus) test result.
Indeterminate QTF-Plus (n = 34) Interpretable QTF-Plus (n = 62)
Unadjusted Model Adjusted Model
p-Value OR (95%CI) p-Value OR (95%CI) p-Value
Gender (male) 22 (64.7%) 45 (72.6%) 0.422 0.693 (0.282–1.700) 0.422
Age (years) 70.5 (56.9–76.2) 63.7 (49.2–74.9) 0.237 1.020 (0.990–1.051) 0.203
Comorbidities
Hypertension 16 (47.1%) 34 (54.8%) 0.466 0.732 (0.316–1.694) 0.466
Dyslipidemia 19 (55.9%) 28 (45.2%) 0.315 1.538 (0.663–3.569) 0.315
Diabetes 11 (32.4%) 12 (19.4%) 0.154 1.993 (0.766–5.182) 0.154
Cardiovascular disease 7 (20.6%) 12 (19.4%) 0.885 1.080 (0.381–3.066) 0.885
Lung disease 6 (17.6%) 9 (14.5%) 0.686 1.262 (0.408–3.906) 0.686
Immunocompromised patient 4 (11.8%) 3 (4.8%) 0.212 2.622 (0.551–12.480) 0.212
Candidate for invasive measures (yes) 25 (73.5%) 52 (83.9%) 0.224 0.534 (0.193–1.480) 0.224
COVID-19 onset to admission (days) 7.5 (5.75–12.25) 8 (7–10.25) 0.401 1.013 (0.928–1.105) 0.778
Laboratory tests (*)
Leukocytes (×109/L) 8.6 (6.3–13.9) 6.8 (5.6–9.6) 0.016 1.131 (1.024–1.248) 0.015
Neutrophils (×109/L) 7.3 (5.4–12.4) 5.5 (3.5–8.3) 0.002 1.147 (1.032–1.274) 0.011
Lymphocytes (×109/L) 0.64 (0.48–1.15) 0.88 (0.64–1.27) 0.017 0.287 (0.105–0.783) 0.015
Serum ferritin (µg/L) (n = 92) 1756 (1081–2574) 1444 (692–2233) 0.159 1.000 (1.000–1.001) 0.201
LDH (U/L) (n = 95) 412 (330–517) 317 (265–424) 0.003 1.005 (1.001–1.008) 0.005 1.005 (1.002–1.008) 0.003
C-reactive protein (mg/L) 79 (29–197) 87 (27–160) 0.654 1.002 (0.997–1.006) 0.447
IL-6 (ng/L),(n = 52) 100 (20–1044) 99 (55–193) 0.955 1.001 (1.000–1.012) 0.130
Troponin (ng/L), (n = 69) 10.0 (7.0–25.0) 10.5 (6.0–18.2) 0.546 1.000 (0.991–1.008) 0.926
D-dimer (µg/L), (n = 93) 636 (353–2913) 361 (250–946) 0.025 1.000 (1.000–1.001) 0.016
Hypoxemia 0.015
None 4 (11.8%) 21 (33.8%) -
Mild 6 (17.6%) 20 (32.3%) 1.557 (0.386–6.423) 0.536
Moderate 22 (64.7%) 20 (32.3%) 5.775 (1.690–19.734) 0.005
Severe 2 (5.9%) 1 (1.6%) 10.5 (0.758–145.359) 0.079
COVID-19 onset to QFT-Plus (days) 11 (9–18) 12 (10-16) 0.797 1.005 (0.937–1.077) 0.893
Severe WHO 8-OS on QFT-time 9 (26.5) 5 (8.1) 0.015 4.104 (1.248–13.491) 0.015
IS prior to QFT-Plus
None 5 (14.7%) 28 (45.1%) 0.003 0.209 (0.072–0.612) 0.003
Corticosteroids 10 (29.4%) 6 (9.7%) 0.013 3.889 (1.270–11.912) 0.013 4.477 (1.397–14.345) 0.012
IL-6 blockage 3 (8.8%) 5 (8.1%) 0.898 1.103 (0.247–4.928) 0.898
Corticosteroids and IL-6 blockage 16 (47.1%) 23 (37.1%) 0.342 1.507 (0.646–3.519) 0.342
Qualitative data are expressed as a number (percentage), and quantitative data are expressed as a median (interquartile range). Abbreviations: OR (95%CI), odds ratio (95% confidence interval); IL-6, interleukin-6;
QFT, QuantiFERON-TB Gold Plus; LDH, lactate dehydrogenase; IS, immunosuppressive drugs; WHO 8-OS, World Health Organization 8-point Ordinal Scale. (*) Laboratory tests when the QFT-Plus assay
was performed.
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4. Discussion
The present study shows an unexpected, high prevalence of indeterminate results in
hospitalized patients with COVID-19. Factors related to COVID-19 clinical severity such
as higher levels of LDH and corticosteroid use before the performance of the QFT-Plus
assay seem to be related to an indeterminate result. Furthermore, a significant associa-
tion between an indeterminate QFT-Plus result and higher in-hospital mortality has also
been found.
The sensitivity of IGRAs in the detection of LTBI can be affected by conditions of
immune dysregulation. Our research group previously assessed IGRAs in several immune-
related disorders, detecting a percentage of indeterminate results of 2.1% in pre-transplant
cirrhotic patients [13], 7.7% in patients with corticosteroids who are going to receive anti-
TNF alpha treatments [14], or 9.5% in HIV-positive patients without antiretroviral treatment
and a CD4 count <100 cells/mm3 [15]. Of great concern, the present study found that 35.4%
of the hospitalized COVID-19 patients studied had an indeterminate QFT-Plus assay result.
This proportion is consistent with the 36.4% rate reported by Torre et al. in a recent work
from an Italian series [10]. So, the frequency of indeterminate results might be significantly
high in COVID-19 patients.
In our study, the QFT-Plus test was mostly performed in severe COVID-19 patients
hospitalized after 10 days of symptoms onset, and the results obtained are representative of
the COVID-19 inflammatory phase [16]. According to previous reports, COVID-19 patients
at this inflammatory stage of the disease show high plasma proinflammatory cytokines
levels (IL-1b, IL-2, IL-4, IL-7, IL-10, MCP-1, GCSF, MIP-1A, TNF-α, IFN-γ and IP-10) [17,18];
however, this fact should not alter the accuracy of the QFT-Plus test since indeterminate
results were not due to a high IFN-γ concentration in the nil tube (>8 UI/mL) [8].
Therefore, we investigated those potential factors which may cause indeterminate
QFT-Plus results due to IFN-γ concentrations in the mitogen-based control below the limit
established by the test manufacturer (that is, nil-corrected mitogen value < 0.5 IU/mL).
Accordingly, our rationale was that COVID-19 patients at severe stages might suffer for
some kind of immunosuppressant condition. According to our data, two groups of fac-
tors might be associated with indeterminate results: firstly, some determinants that have
been previously related to worse COVID-19 outcome (lymphopenia, leukocytosis, neu-
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trophilia, LDH, D-dimer, hypoxemia) [17,19] and, secondly, the use of immunosuppressive
treatments administered before the QFT-Plus assay, especially corticosteroids.
Corticosteroids and other immunosuppressive drugs are well known to be the cause
of indeterminate QFT-Plus assay results [14]. However, it should be noted that the indeter-
minate results rate remained high (14.7%) even in the subset of our studied patients who
had not received any immunosuppressive treatment prior to test, highlighting COVID-19
itself as a determining factor of an indeterminate result.
SARS-CoV-2 has evolved several mechanisms to impair host immune response, in-
cluding the inhibition of IFN induction and signaling. In fact, impaired IFN-I/III signatures
have been related to a persistent blood viral load and an inflammatory disturbance that
leads to a worse COVID-19 prognosis [18,20]. Nevertheless, there are conflicting data
regarding the role of type II IFNs such as IFN-γ. In several studies, elevation of multiple in-
flammatory cytokines, including IFN-γ, has been related to a more severe COVID-19 [18,21].
On the other hand, recent data show that COVID-19 has the ability to induce an early and
profound suppression of T-cell IFN-γ production [22]. Possibly, these data suggest that
timing is the key, as IFN-γ could be protective early in a disease but later could become
pathologic and increase as a consequence of multiple stimuli received by the hyperinflam-
matory cytokine storm. In clinical practice, there is a lack of diagnostic tools to evaluate
the failure of host protective immunity while suffering from COVID-19. In this respect, the
QFT-Plus test might be a standardized and accessible functional immunoassay to study the
IFN- γ host immunity.
Worryingly, the rate of patients with an indeterminate QFT-Plus assay result was
higher in patients who died during admission (64.7% vs. 29.1%). Several factors have
been related to in-hospital mortality in COVID-19 [14,16], but there is scarce information
regarding the role of an indeterminate QFT-Plus result as a marker of severity or death.
This preliminary investigation of COVID-19 patients with an indeterminate QFT-
Plus assay result has several limitations that deserve further comment. We performed
a retrospective analysis so confounders could be overlooked and missing data might
have altered some results. Only 6.8% of COVID-19 patients admitted to hospital were
tested for QFT-Plus assay, and therefore this is a highly selected group with potential for
bias. Furthermore, the QFT-Plus assay was unsystematically performed in hospitalized
patients with COVID-19, although in most cases was done in those who transited into
inflammatory stages receiving or going to receive immunosuppressive agents such as
corticosteroids and/or tocilizumab. Therefore, the present study does not allow us to
assess the QFT-Plus assay usefulness in patients at earlier stages of the disease. The number
of COVID-19 patients on whom a QFT-Plus assay was performed is relatively low to draw
solid conclusions about its role in predicting clinical outcomes of the disease.
5. Conclusions
The indeterminate QFT-Plus assay results show an unexpected, high prevalence in
hospitalized COVID-19 patients with host-immune hyperinflammatory syndrome, losing
reliability in this context. Factors related to worse COVID-19 outcome such as LDH,
as well as corticosteroid use before the QFT-Plus assay, seem to be predictors for an
indeterminate result. Furthermore, indeterminate QFT-Plus results were found in a higher
proportion in those COVID-19 patients who died. Therefore, further and larger studies are
needed to assess the real significance of indeterminate QFT-Plus test results on COVID-19
clinical outcomes.
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